Beam base-edited sickle cell therapy succeeds in pivotal trial

· Health · United States

Beam Therapeutics said Tuesday that its base-edited sickle cell therapy succeeded in a Phase 1/2 clinical trial, meeting the study’s goal. BioPharma Dive reported the result is a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year. Endpoints News said the success means a third one-time therapy for sickle cell disease may soon enter the market. The company’s approach uses base editing. The immediate effect is that Beam can move toward regulatory submission and join the small group of one-time sickle cell treatments.

Why it matters：A successful base-editing trial would add a third one-time sickle cell option and test whether newer editing approaches can become approved therapies.

Key points

  • The trial was a Phase 1/2 study.
  • Beam could file with the FDA as soon as the end of the year.
  • It would be a first-of-its-kind FDA application and a third one-time sickle cell therapy.

Sources (original reporting)

More stories from this day